OPKO Health, Inc. (OPK)Healthcare | Diagnostics & Research | Miami, United States | NasdaqGS
1.37 USD
+0.05
(3.788%)
⇧
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 1.37 |
Hot Take ↕ | Oct. 10, 2026, 3:48 a.m. EDT
The long-term investment case remains severely compromised by a decade-long structural decline, with the stock trading at less than half its 2016 peak despite a recent minor price uptick. While the company reports shrinking losses and pipeline progress, the balance sheet carries heavy debt relative to equity, and the business continues to burn operating cash. The negative earnings per share and lack of a dividend payout reflect the reality that this is a turnaround story far from resolution, not a stable income vehicle. Short-term momentum is fragile; while the stock recently hit a 52-week high, the broader technical picture shows it still trades well below its 50-day moving average, and the overwhelming options activity suggests traders are hedging against further drops rather than betting on an immediate surge. Until the debt load is managed and consistent profitability is proven, the risk profile remains extreme. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.086922 |
| AutoTheta | 0.100629 |
| AutoETS | 0.102830 |
| AutoARIMA | 0.102852 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.305 |
| Excess Kurtosis | -1.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 33.617 |
| Revenue per Share | 0.754 |
| Market Cap | 1,022,469,696 |
| Forward P/E | -5.07 |
| Beta | 1.50 |
| Profit Margins | -12.40% |
| Website | https://www.opko.com |
As of Oct. 10, 2026, 3:48 a.m. EDT: Speculators are heavily positioned for downside protection, with significant open interest in out-of-the-money puts expiring in late 2026 and early 2027. Call activity is concentrated near the money and slightly out-of-the-money, suggesting a speculative bid for a rebound rather than a strong conviction in a major breakout. The disparity in volume and open interest between puts and calls indicates a market expecting continued volatility or further declines.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08666664 |
| Address1 | 4,400 Biscayne Boulevard |
| All Time High | 19.2 |
| All Time Low | 0.21 |
| Ask | 1.54 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 1,798,430 |
| Average Daily Volume3 Month | 3,241,096 |
| Average Volume | 3,241,096 |
| Average Volume10Days | 1,798,430 |
| Beta | 1.504 |
| Bid | 1.15 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | 1.587 |
| City | Miami |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.37 |
| Current Ratio | 3.349 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 1.37 |
| Day Low | 1.3024 |
| Debt To Equity | 33.617 |
| Display Name | OPKO Health |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,184,200 |
| Earnings Call Timestamp Start | 1,785,184,200 |
| Earnings Timestamp | 1,785,182,400 |
| Earnings Timestamp End | 1,793,217,600 |
| Earnings Timestamp Start | 1,793,217,600 |
| Ebitda | -78,172,000 |
| Ebitda Margins | -0.13297 |
| Enterprise To Ebitda | -14.325 |
| Enterprise To Revenue | 1.905 |
| Enterprise Value | 1,119,791,616 |
| Eps Current Year | -0.21 |
| Eps Forward | -0.27 |
| Eps Trailing Twelve Months | -0.09 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.507 |
| Fifty Day Average Change | -0.13699996 |
| Fifty Day Average Change Percent | -0.09090907 |
| Fifty Two Week Change Percent | -8.666664 |
| Fifty Two Week High | 1.75 |
| Fifty Two Week High Change | -0.38 |
| Fifty Two Week High Change Percent | -0.21714285 |
| Fifty Two Week Low | 0.98 |
| Fifty Two Week Low Change | 0.39 |
| Fifty Two Week Low Change Percent | 0.39795917 |
| Fifty Two Week Range | 0.98 - 1.75 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 815,322,600,000 |
| Float Shares | 323,727,331 |
| Forward Eps | -0.27 |
| Forward P E | -5.074074 |
| Free Cashflow | 54,760,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,275 |
| Fullday Change | 0.049999952 |
| Fullday Change Percent | 3.787875 |
| Fullday Price | 1.37 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.19472 |
| Gross Profits | 114,477,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.50521 |
| Held Percent Institutions | 0.27565 |
| Implied Shares Outstanding | 746,328,225 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Ir Website | http://investor.opko.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida. |
| Long Name | OPKO Health, Inc. |
| Market | us_market |
| Market Cap | 1,022,469,696 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_33405327 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -72,890,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,268,757,982 |
| Number Of Analyst Opinions | 4 |
| Open | 1.31 |
| Operating Cashflow | -123,378,000 |
| Operating Margins | -0.15309 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Peg Ratio | 93.65 |
| Phone | 305 575 4100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.37 |
| Post Market Time | 1,792,010,950 |
| Previous Close | 1.32 |
| Price Eps Current Year | -6.52381 |
| Price Hint | 4 |
| Price To Book | 0.863264 |
| Price To Sales Trailing12 Months | 1.7391987 |
| Profit Margins | -0.12398 |
| Quick Ratio | 2.651 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.05 |
| Regular Market Change Percent | 3.78788 |
| Regular Market Day High | 1.37 |
| Regular Market Day Low | 1.3024 |
| Regular Market Day Range | 1.3024 - 1.37 |
| Regular Market Open | 1.31 |
| Regular Market Previous Close | 1.32 |
| Regular Market Price | 1.37 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 1,635,569 |
| Return On Assets | -0.05519 |
| Return On Equity | -0.05876 |
| Revenue Growth | 0.043 |
| Revenue Per Share | 0.754 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 746,328,225 |
| Shares Percent Shares Out | 0.0476 |
| Shares Short | 35,560,259 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 34,558,372 |
| Short Name | Opko Health, Inc. |
| Short Percent Of Float | 0.0857 |
| Short Ratio | 12.42 |
| Source Interval | 15 |
| State | FL |
| Symbol | OPK |
| Target High Price | 8.5 |
| Target Low Price | 3.0 |
| Target Mean Price | 4.375 |
| Target Median Price | 3.0 |
| Total Cash | 300,760,992 |
| Total Cash Per Share | 0.403 |
| Total Debt | 398,083,008 |
| Total Revenue | 587,897,024 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.09 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.32545 |
| Two Hundred Day Average Change | 0.04455006 |
| Two Hundred Day Average Change Percent | 0.033611275 |
| Type Disp | Equity |
| Volume | 1,635,569 |
| Website | https://www.opko.com |
| Zip | 33,137 |